The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Roflumilast (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms MOVE
- Sponsors AstraZeneca
- 04 May 2012 Company added (Takeda Global Research and Development Center) as reported by ClinicalTrials.gov.
- 24 Aug 2007 The expected completion date for this trial is now 1 Aug 2005.
- 30 Oct 2005 New trial record.